Trials / Withdrawn
WithdrawnNCT03768531
Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer
Safety and Tolerability Study of Combination Nivolumab and Cabiralizumab as Neoadjuvant and Adjuvant Therapy for Resectable Biliary Tract Cancer
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
The purposed of this research is to study the safety and clinical activity of the combination of nivolumab and cabiralizumab in people with resectable biliary tract cancers (BTC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | Nivolumab 3 mg/kg will be given intravenously (IV) through a vein in the arm over 30 minutes every 2 weeks. (Cycle length 2 weeks). |
| DRUG | Cabrilizumab | Cabiralizumab 4 mg/kg given IV for 30 minutes, 30 minutes after Nivolumab infusion is completed, every 2 weeks. (Cycle length 2 weeks). |
Timeline
- Start date
- 2019-06-14
- Primary completion
- 2023-01-01
- Completion
- 2023-01-01
- First posted
- 2018-12-07
- Last updated
- 2020-04-13
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03768531. Inclusion in this directory is not an endorsement.